Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY 94-9027 for Severe Haemophilia A: A Post Hoc Analysis

INTRODUCTION: BAY 94-9027 is a newly developed extended half-life product to treat haemophilia, allowing for fewer injections than with standard products. This post hoc analysis aimed to compare physicians’ and patients’ opinions on BAY 94-9027 prophylaxis, and explore how qualitative interview data...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Adv Ther
Asıl Yazarlar: Lalezari, Shadan, Acquadro, Michaël, de Bock, Elodie, Lambert, Jérémy, Simpson, Mindy L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Healthcare 2020
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7467448/
https://ncbi.nlm.nih.gov/pubmed/32410165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-020-01374-2
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller